Lilly’s Cymbalta approved for expanded use

Eli Lilly and Co.’s antidepressant drug Cymbalta has been approved by the Food and Drug Administration to treat generalized anxiety disorder. About 6.5 million Americans suffer for the disorder. The drug is currently marketed to treat depression and to manage diabetes-related pain. In 2006, Cymbalta sales were $1.3 billion, up from $679 million the year before.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.